Important Safety Information including Boxed Warning and Indication

Important Safety Information for Osphena®

WARNING: Endometrial Cancer and Cardiovascular Disorders

Osphena® is an estrogen agonist/antagonist with tissue selective effects. In the endometrium Osphena® has estrogen agonistic effects. There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogen therapy. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

The Women’s Health Initiative (WHI) estrogen-alone sub study reported an increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg], relative to placebo. Osphena® 60 mg had thromboembolic and hemorrhagic stroke incidence rates of 0.72 and 1.45 per thousand women vs. 1.04 and 0 per thousand women for placebo and a DVT incidence rate of 1.45 vs. 1.04 per thousand women for placebo. Osphena® should be prescribed for the shortest duration consistent with treatment goals and risks for the individual woman.


  • Undiagnosed abnormal genital bleeding
  • Known or suspected estrogen-dependent neoplasia
  • Active deep vein thrombosis (DVT), pulmonary embolism (PE), or a history of these conditions
  • Active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions
  • Hypersensitivity (for example, angioedema, urticaria, rash, pruritus) to Osphena® or any of its ingredients
  • Women who are or may become pregnant. Osphena® may cause fetal harm when administered to a pregnant woman. Ospemifene was embryo-fetal lethal with labor difficulties and increased pup deaths in rats at doses below clinical exposures, and embryo-fetal lethal in rabbits at 10 times the clinical exposure based on mg/m2. If this drug is used during pregnancy, or if a woman becomes pregnant while taking this drug, she should be apprised of the potential hazard to a fetus.

Warnings and Precautions

In Osphena® clinical trials of up to 15 months, the incidence rates compared to placebo for thromboembolic and hemorrhagic stroke were 0.72 Osphena® 60 mg vs. 1.04 placebo and 1.45 Osphena® 60 mg vs. 0 placebo per thousand women. Should thromboembolic or hemorrhagic stroke occur or be suspected, Osphena® should be discontinued immediately. In clinical trials, a single MI occurred in a woman receiving Osphena® 60 mg.

Incidence rate of DVT was 1.45 Osphena® vs. 1.04 placebo per thousand women. Should a VTE occur or be suspected, Osphena® should be discontinued immediately. Osphena® should be discontinued at least 4 to 6 weeks before surgery with increased risk of thromboembolism or during periods of prolonged immobilization.

There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogen therapy. The risk appears dependent on duration of treatment and estrogen dose. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. However, studies suggest a possible increased risk for breast cancer in patients receiving estrogen plus progestin therapy.

Osphena® is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, Osphena® has agonistic effects. In Osphena® clinical trials, no cases of endometrial cancer were seen with exposure up to 52 weeks. There was a single case of simple hyperplasia without atypia. Endometrial thickening equal to 5mm or greater was reported at a rate of 60.1 Osphena® vs. 21.2 placebo per 1000 women. Uterine polyps occurred at an incidence of 5.9 Osphena® vs. 1.8 placebo per 1000 women, and any type of proliferative endometrium (weakly plus active plus disordered) was 86.1 Osphena® vs. 13.3 placebo per 1000 women.

Osphena® has not been adequately studied in women with breast cancer; therefore it should not be used in women with known or suspected breast cancer or with a history of breast cancer.

Osphena® should not be used in women with severe hepatic impairment as it has not been studied.

In clinical trials the more commonly reported adverse reactions in ≥1 percent of patients treated with Osphena® 60 mg compared to placebo were: hot flush (7.5% vs. 2.6%), vaginal discharge (3.8% vs. 0.3%), muscle spasms (3.2% vs. 0.9%), hyperhidrosis (1.6% vs. 0.6%), and genital discharge (1.3% vs. 0.1%).

The following adverse reactions have been identified during post-approval use of ospemifene:

Immune System Disorders: allergic conditions including hypersensitivity, angioedema.
Nervous System Disorders: headache
Skin and Subcutaneous Tissue Disorders: rash, rash erythematous, rash generalized, pruritus, urticaria.

Drug interactions: Do not use estrogens or estrogen agonists/antagonists, fluconazole, or rifampin concomitantly with Osphena®. Co-administration of Osphena® with drugs that inhibit CYP3A4 and CYP2C9 may increase the risk of Osphena®-related adverse reactions. Osphena® is highly protein bound. Use cautiously with highly protein bound drugs as use with other highly protein-bound drugs may lead to increase exposure of that drug or ospemifene.

Please click for U.S. Full Prescribing Information for Osphena® (ospemifene) tablets, including Boxed Warning, and Patient Information.


Osphena® (ospemifene) is indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

For U.S. Healthcare Professionals Only

Osphena® Patient Savings

How to ePrescribe 

If you choose to ePrescribe, select ProCare Pharmacy Care:
  1. Not listed in your software program? See below to conduct a system search:
    Select “Retail” pharmacy as opposed to “Mail Order” pharmacy to do your search, if that is an option.
  2. Most ePrescribing systems have a search library. Begin by using the following search criteria only:
    • “ProCare Pharmacy Care”
    • “Miramar, Florida 33025”
    • “NCPDP #1098121”
  3. If ProCare Pharmacy Care does not appear in the system, please add the following criteria:
    • NCPDP #1098121
    • Address: 3891 Commerce Parkway
    • If NPI# is required: 1427160357
    • If you are still not able to find ProCare Pharmacy Care, contact your ePrescribing software vendor and log a case to have the pharmacy added to your system.
  • This offer is not available to individuals enrolled in Medicare, Medicaid, TRICARE or any other federal or state healthcare plan.
  • Federal law prohibits the selling, purchasing, trading or counterfeiting of this offer. Such activities may result in imprisonment of up to 10 years, fines of up to $250,000, or both.
  • This offer is only good in the United States. Duchesnay USA reserves the right to rescind, revoke or amend this offer without notice at any time.
  • Patients and pharmacies are responsible for disclosing to insurance carriers the redemption and value of the CoPay and complying with any other conditions imposed by insurance carriers or third-party payers.
  • Void where prohibited by law.
Osphena product inquiries: 1-855-OSPHENA (677-4362)
Osphena At Home® questions or to prescribe by phone: 1-844-716-HOME (4663)

Please see Important Safety Information and Full Prescribing Information, including Boxed Warning regarding Endometrial Cancer and Cardiovascular Disorders.